



BUILDING BETTER



Investor Presentation

Q4 FY23

10 May 2023

Safe Harbor Statement



Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.


Risks and uncertainties include general industry and market conditions, domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances, regulatory environment and patents obtained by competitors. Challenges inherent in new product development include but are not limited to completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and international operations. Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and failure to gain market acceptance. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of the meeting.

Lupin Limited does not undertake any obligation to update forward-looking statements to reflect new information, future events, or otherwise after the date thereof.



LUPIN

Lupin at a Glance



Lupin Today

Operating from a Position of Strength



Global Presence



12th
Largest Generic
Company

(by sales¹)



\$2 bn

Annual sales in FY23



\$233 mn

EBITDA in FY23



21,300+
Lupinytts

Reaching lives in
100+ countries

Local Leadership

3rd

Largest in
the US
(by prescriptions³)

6th

India Pharma
Market Rank
(by sales³)

4th

Largest
Australia
Gx
(by sales⁴)

8th

South Africa
Gx
(by sales)

With Global Infrastructure


15 Manufacturing
Sites

7 R&D
Sites

across India, the US, Netherlands,
Brazil and Mexico

Geographically Diverse

(FY23 Sales)



And Growing Sustainably²



**>10% reduction in Scope 1
and 2 emissions**

Renewable energy
share of ~6.5%

Adding 22MW
Renewable energy
capacity in FY24

Vision

A Pharmaceutical Company Focused on Delivering High Quality Medicines to Patients Around the World



United States

Evolving portfolio and pipeline in Complex platforms (Inhalation, Biosimilars and Injectables)
Scaled product platforms in legacy oral, ophthalmic and dermatology

Global Developed Markets

Global operational efficiency and presence driving leverage on CAPEX and R&D across the platforms through markets with similar regulatory regimes (UK, Europe, Canada and Australia)

India Region

Delivering innovative brands at above market Growth through organic and in-organic means, as well as establishing strategic market adjacencies

Other Emerging Markets

Global reach and scale positions us as a partner of choice in South Africa, Brazil, Mexico, Philippines
Enhancing Access to Medicines in anti-TB in low and middle income nations

API

Meaningful scale achieving competitive costs to serve internal as well as external customers and contribute meaningfully to Global Public Health

Continuous Improvement Culture


Best in Class Global Quality



LUPIN



Q4 FY23 Performance






Q4 FY23 Key Highlights

Continued focus on profitable growth








Key Metrics



Business Performance


INR in mn



Q4 FY23 Financial Snapshot



Sales Mix



Key Financials


INR in mn

	Q4 FY23	Q3 FY23	Q4 FY22
Sales	43,303	42,446	38,645
EBITDA	6,150	5,506	2,823
PBT	2,585	2,461	(864)

India: An ongoing story of sustained outperformance



Lupin has grown better than the market ex-in-licensed portfolio across FY23



Cardiac and respiratory are back on growth trajectory

- Cardiac, GI, Respiratory and Gynaecology registered double-digit growth since H2 FY23
- Diabetes is recovering from impact of patent expiries in segment

Lupin grew close to par with market at 14.3% in Q4 excluding in-licensed portfolio

Leveraging leadership by adding 6 new divisions

#2 rank
Respiratory

#3 rank
Diabetes Care

#3 rank
Cardiac

Leveraging therapy strength by adding ~1,000 ME in 6 new divisions to reach ~7,000 Total MEs¹ and 9,100 total sales force

Gaining significant launch momentum with multiple new introductions in the quarter

1 in
Diabetes Care

2 in
Cardiac

1 in
Anti-infective

- Launched a total of 16 products with 53 SKUs in FY23
- Poised to launch ~21 products in FY24

Note:
1. As of 31-Mar-23

North America: Investing to increase complex share




Leadership: Delivering ~5.5% TRx Gx volume of the U.S.¹

#3
in the US¹
Maintaining leadership

#1
in 41 products²
Top 3 in 109 products²

New product sales driving US growth (\$ mn)



Growing Respiratory portfolio

20.5%
Albuterol market share
In generics

48.0%
Arfometerol market share
Brand + generic

Q4 FY23 Key Highlights

- Focused on profitable growth in base portfolio
- Continued strength in in Q4FY23
- Total 9 launches in FY23 with Suprep performing well
- USFDA Inspections: Vizag, Lupin Bio-research center and Pharmacovigilance had zero observations

Evolving Complex Product Portfolio through investments in Injectables, Inhalation and Biosimilars

- Current pipeline includes 55 FTFs incl. 22 exclusive FTF
- Substantial investments in Inhalation, Injectables and Biosimilars pipeline and capabilities (Development and Manufacturing)
- 155 ANDAs pending approval; 30+ strong pipeline of Injectables (filed + under development)

Note:
1. IQVIA Qtr Gx Mar-23 by prescriptions
2. iQVIA Qtr Mar-23 NSP data

Other Markets: Key Highlights



Other Key Markets driving growth



EU

- Successful MHRA inspection of Pithampur facilities
- Acquired Medisol in France – unique hospital business




South Africa

- 8th largest generics player¹
- 35% QoQ growth to reach ZAR 417 mn sales in Q4 FY23



Australia

- 4th largest generics player²
- SCP acquisition performing well



API + Global Institutional

- API revenues grew 46% QoQ in Q4 FY23 due to core API business growth
- Continued leadership in anti-TB Institutional business and increased ARV presence

Emerging Markets: Steady growth



Brazil

- BRL 75 mn sales in Q4 FY23 (growth 24% LCL YoY);
- In reference market, ranks 10th position in value terms³



Mexico

- Market leader in Ophthal (#2 in units and #5 in value)³






Philippines

- Strong QoQ growth of 20% Q4FY23 to reach PHP542 mn


Note:
 1. IQVIA Feb23 by sales
 2. IQVIA Midas Sales Audit Dec-22

3. IQVIA MAT Jan-23

Key Financial Metrics: FY23 Quarterly Trend




P&L Highlights- Q4 FY23



Amount in INR mn	Q4FY23	% of Sales	Q3FY23	% of Sales	QoQ Growth	Q4FY22	% of Sales	YoY Growth
Sales	43,303	100.0%	42,446	100.0%	2.0%	38,645	100.0%	12.1%
Other operating income	998	2.3%	776	1.8%	28.6%	185	0.5%	439.5%
Total revenue	44,301	102.3%	43,222	101.8%	2.5%	38,830	100.5%	14.1%
Gross Profit (excl. other operating income)	25,802	59.6%	25,375	59.8%	1.7%	22,323	57.8%	15.6%
EBITDA	6,150	14.2%	5,506	13.0%	11.7%	2,823	7.3%	117.8%
PBT before exceptional item	2,585	6.0%	2,461	5.8%	5.0%	-864	-2.2%	NM
Exceptional item ¹	-	-	-	-	-	-12	-	
PBT after exceptional item	2,585	6.0%	2,461	5.8%	5.0%	-852	-2.2%	NM
Profit after Tax	2,424	5.6%	1,576	3.7%	53.8%	-5,119	-13.2%	NM
Profit/(Loss) for the period	2,360	5.4%	1,535	3.6%	53.7%	-5,180	-13.4%	NM

NM: Not Meaningful

P&L Highlights- FY23




Amount in INR mn	FY2023	% of Sales	FY2022	% of Sales	YoY Growth
Sales	162,700	100.0%	161,928	100.0%	0.5%
Other operating income	3,717	2.3%	2,127	1.3%	74.8%
Total revenue	166,417	102.3%	164,055	101.3%	1.4%
Gross Profit (excl. other operating income)	94,902	58.3%	97,116	60.0%	-2.3%
EBITDA	18,715	11.5%	23,073	14.2%	-18.9%
PBT before exceptional item	7,165	4.4%	12,135	7.5%	-41.0%
Exceptional item	-	0.0%	25,861	16.0%	-100.0%
PBT after exceptional item	7,165	4.4%	-13,726	-8.5%	NM
Profit after Tax	4,477	2.8%	-15,097	-9.3%	NM
Profit/(Loss) for the period	4,301	2.6%	-15,280	-9.4%	NM

NM: Not Meaningful

ESG: FY23 Updates and Future Initiatives

Our Commitment to Responsible Business Practices, Sustainability, Environmental Stewardship and Proactive Risk Management



Lupin – Awards and Accolades



Organizational Awards

- **ATD (Association of Talent Development) BEST Award**
- **‘Factories of the Future’ at the Economic Times Promising Plant Awards 2022**
- Excellence in Patient Centric Initiative at **Zee Health Awards 2022**
- **‘Digital Pharma Marketing Excellence Award’ for ‘in Pharma Digital Marketing & Awards 2022**
- Businessworld's **Diversity and Inclusion Award 2022** for "**Outstanding Diversity Network**"
- **Cyber Security Excellence Awards 2022** for the **Best Zero Security** in Healthcare
- **Bioprocessing Excellence in South Asia Award** at Asia Pacific Bioprocessing Excellence Awards 2022 by **IMAPAC**

Leadership and Other Awards

- **Vinita Gupta**, named among India’s **20 Most Influential Women** in Healthcare by 2022 BW Healthcare World
- **Goa and Nagpur** awarded **Gold Medal** at the National Awards for **Manufacturing Competitiveness 2022-23**
- **Pithampur** team wins **two awards** - at the **CII National Technology Competition** and won **four** awards at **43rd CII National Kaizen Competition**
- **Dabhasa** Recognized in the **silver category** at the **India Green Manufacturing Challenge 2021-22** organized by International Research Institute for Manufacturing
- Lupin's corporate communication team named among the **Top 30 Corporate Communications Team** for 2022 by Reputation Today
- Global Supply Chain team won the **‘Apex 10 Supply Chains (West)’** award at the **Top 200 Supply Chains Awards (West)**
- LHWRF won the Water Sustainability Awards 2022-23 for Excellence in **Participatory Water Management**
- Lupin Diagnostics won **Best Pathology Lab (National Category)** at **The Economic Times ET Healthcare Awards 2022**





Thank you



REGISTERED OFFICE

3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai – 400 055. India,
Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com

 youtube.com/c/LupinGlobal

 twitter.com/LupinGlobal

 linkedin.com/company/lupin/

 facebook.com/LupinWorld/